
    
      This study aims to use convalescent plasma as experimental treatment in critically ill
      Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
      Donors must have anti-SARS CoV2 antibodies. Recipients must be critically ill Covid-19
      patients on mechanical ventilation.
    
  